CanaQuest, formally known as Algae Dynamics, has eliminated the capital requirements for extraction and formulation equipment. We are now discussing profit sharing business ventures with potential partners with the appropriate Health Canada licenses to produce and sell cannabis and medical formulated products, utilizing our patented formulations.



SEC Filings
Annual Special Meeting : 1/19
Audio Interview
CEOCFO Magazine Interview
ADC Goes to Pot

News & Press

603, 2018


March 6th, 2018|0 Comments

TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- ALGAE DYNAMICS CORP (OTC: “ADYNF”) (the "Company"), a company focused on the development of unique health products and nutraceuticals utilizing cannabis and algae oils, today provided a corporate [...]

Collaboration Partners

Strategic International Licensed Producer/Processor/Distributor: We have executed a Master Cannabis Supply Agreement for medical cannabis product supply and a preliminary Production-Distribution Agreement with Jamaican Medical Cannabis Corporation (“JMCC”), JMCC is a Canadian-headquartered group of companies with rapidly expanding medical cannabis operations in Jamaica. Providing a range of cultivars sun-grown in specially designed greenhouses at various locations around the island, JMCC also offers an integrated and customizable outsourcing solution for the global medical cannabis industry, including processing/extraction, testing, global warehousing and distribution. Led by an international executive team with in-depth experience in highly regulated industries, JMCC provides premium medicinal cannabis and associated services to licensed producers and other industry participants to free them to focus on creating and delivering the best products for patients.

Licensed Producers: We have engaged in several discussions with major Licensed Producers/Distributors to sell medicinal cannabis domestically and Internationally (supplied by JMCC). As well, these companies are reviewing the strength of our IP to potentially facilitate the processing and distribution of our formulations because our formulated products do not compete with their product lines.

Licensed Processor/Pharmaceutical Company: We have engaged in several discussions with a major pharmaceutical company, international distributor and GMP manufacturer who has provided highly positive feedback of the approach Dr. Laviolette has adopted in his research and pre-clinical animal trials, the depth of research and the effective integration of the various research departments at Western University. We believe we can leverage their expertise with multiple formulations, delivery systems for improved bioavailability, including by integrating our formulation into soft gels and tablets for timed release of the formulations. We would also expect to take advantage of their supply, processing and distribution capabilities and collaborate further on R & D and human trials for our formulations.

We have reviewed our strategy and believe it is more efficient to partner with existing Licensed Producers who have facilities compliant with good manufacturing practices (GMP) necessary for the preparation of our formulations. Additionally, we are seeking our own purchase/sales, import/export license without possession under the Cannabis Act to distribute formulations and develop our brand as permitted under the Cannabis Act Regulations. We have included a full description of the cannabis-related licensing process at the end of this Business Description section for further information and disclosure. We do not require similar special licensing with respect to algae related sales.